市场调查报告书
商品编码
1291344
血红蛋白病市场:2023-2028年全球行业趋势、份额、规模、增长、机会和预测Hemoglobinopathies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 |
2022年,全球血红蛋白病的市场规模达到92亿美元。展望未来,IMARC集团预计,到2028年,市场规模将达到163亿美元,在2023-2028年期间表现出9.39%的增长率(CAGR)。
血红蛋白病是导致血红蛋白分子结构和生产异常的遗传性血液疾病。镰状细胞、地中海贫血、血红蛋白C和β-地中海贫血是一些常见的血红蛋白病类型。血红蛋白病可通过基因检测、高效液相色谱法检测血红蛋白、常规红细胞(RBC)计数、血红蛋白等电聚焦(Hb IEF)和血红蛋白电泳(Hb ELP)试验来检测。皮肤苍白、呼吸急促、手脚冰凉、疲倦、疼痛、手脚肿胀是血红蛋白病的几个最常见的症状。一些广泛使用的血红蛋白病治疗方案包括抗生素、ACE抑制剂、干细胞移植、输血、羟基脲和止痛剂。
镰状细胞病(SCD)和地中海贫血症等各种病症的发病率越来越高,是推动市场增长的关键因素之一。血红蛋白病是由异常的血红蛋白引起的,它使红细胞变形和损坏,并使红细胞变硬和粘稠。与此相呼应,贫血患病率的上升,特别是在老年人口中,也容易受到各种其他慢性疾病的影响,有利于市场的增长。各种技术进步,如CRISPR-Cas9技术的发展,通过编辑、删除、添加或改变基因和修改DNA来治疗血红蛋白病,正在为市场增长提供动力。与此相呼应,广泛采用基因疗法治疗血红蛋白病有利于市场增长。其他因素,如医疗保健行业的大幅扩张,以及政府实施各种倡议促进研究和开发(R&D)活动,以可承受的成本推出治疗血红蛋白病的新型疗法,预计将为市场提供积极的前景。
The global hemoglobinopathies market size reached US$ 9.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 16.3 Billion by 2028, exhibiting a growth rate (CAGR) of 9.39% during 2023-2028.
Hemoglobinopathies is genetic blood disorder that causes structural and production abnormalities in hemoglobin molecules. Sickle cell, thalassemia, hemoglobin C, and beta-thalassemia are some of the common types of hemoglobinopathies. Hemoglobinopathies are detected by genetic testing, hemoglobin by high-performance liquid chromatography, routine red blood cell (RBC) count, hemoglobin isoelectric focusing (Hb IEF), and hemoglobin electrophoresis (Hb ELP) test. Pale skin, shortness of breath, cold hands or feet, tiredness, pain, and swelling in the hands and feet are a few of the most common symptoms hemoglobinopathies. Some of the widely used hemoglobinopathies treatment solutions include antibiotics, ACE inhibitors, stem-cell transplantation, blood transfusions, hydroxyurea, and analgesic.
The increasing prevalence of various medical conditions, such as sickle cell disease (SCD) and thalassemia, is one of the key factors driving the growth of the market. Hemoglobinopathies are caused by abnormal hemoglobin that deforms and damages red blood cells and makes them hard and sticky. In line with this, the rising prevalence of anemia, especially among the geriatric population, which is also susceptible to various other chronic ailments, is favoring the market growth. Various technological advancements, such as the development of CRISPR-Cas9 technology to cure hemoglobinopathies by editing, removing, adding, or altering genes and modifying the DNA, are providing an impetus to the market growth. In line with this, the widespread adoption of gene therapy for the treatment of hemoglobinopathy is favoring market growth. Other factors, such as the significant expansion in the healthcare industry, along with the implementation of various government initiatives to promote research and development (R&D) activities to introduce novel therapies for treating hemoglobinopathies at affordable costs is anticipated to provide a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global hemoglobinopathies market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, treatment, test type and end user.
Thalassemia
Alpha Thalassemia
Beta Thalassemia
Sickle Cell Disease
Others
The increasing prevalence of various medical conditions, such as sickle cell disease (SCD) and thalassemia, is one of the key factors driving the growth of the market. Hemoglobinopathies are caused by abnormal hemoglobin that deforms and damages red blood cells and makes them hard and sticky. In line with this, the rising prevalence of anemia, especially among the geriatric population, which is also susceptible to various other chronic ailments, is favoring the market growth. Various technological advancements, such as the development of CRISPR-Cas9 technology to cure hemoglobinopathies by editing, removing, adding, or altering genes and modifying the DNA, are providing an impetus to the market growth. In line with this, the widespread adoption of gene therapy for the treatment of hemoglobinopathy is favoring market growth. Other factors, such as the significant expansion in the healthcare industry, along with the implementation of various government initiatives to promote research and development (R&D) activities to introduce novel therapies for treating hemoglobinopathies at affordable costs is anticipated to provide a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global hemoglobinopathies market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, treatment, test type and end user.
Thalassemia
Alpha Thalassemia
Beta Thalassemia
Sickle Cell Disease
Others
Blood Transfusion
Stem-cell Transplantation
Analgesics
Antibiotics
ACE Inhibitors
Hydroxyurea
Others
Red Blood Cell (RBC) Count
Genetic Testing
High Performance Liquid Chromatography (HPLC)
Hemoglobin Isoelectric Focusing (Hb IEF)
Hemoglobin Electrophoresis (Hb ELP)
Hemoglobin Solubility Test
Hospitals and Clinics
Diagnostics Laboratories
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Bio-Rad Laboratories Inc., bluebird bio Inc., Bristol-Myers Squibb Company, Danaher Corporation, Emmaus Life Sciences Inc., Gamida-Cell Ltd., Global Blood Therapeutics Inc., Novartis AG, PerkinElmer Inc., Pfizer Inc., Prolong Pharmaceuticals LLC, Sangamo Therapeutics Inc. and Sysmex Corporation.
Key Questions Answered in This Report
1. What was the size of the global hemoglobinopathies market in 2022?
2. What is the expected growth rate of the global hemoglobinopathies market during 2023-2028?
3. What has been the impact of COVID-19 on the global hemoglobinopathies market?
4. What are the key factors driving the global hemoglobinopathies market?
5. What is the breakup of the global hemoglobinopathies market based on the type?
6. What is the breakup of the global hemoglobinopathies market based on the treatment?
7. What are the key regions in the global hemoglobinopathies market?
8. Who are the key players/companies in the global hemoglobinopathies market?